One Hit in Hand, Alexion Tries to Repeat After $8.4 Billion DealBy
Drugmaker expands rare-disease strategy through acquisitions
New treatment praised in medical journal before FDA decision
Alexion Pharmaceuticals Inc. made its name selling one drug, Soliris, to a tiny handful of patients around the world for hundreds of thousands of dollars a year each. It’s been a lucrative model -- one the company is now trying to prove was no fluke.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.